An Assistive Electronic Patient-Reported Outcome Monitoring Intervention for Management of Immune-Related Toxic Effects-Moving Toward Efficiency and Scale

Samuel U Takvorian¹, Tara L Kaufmann^{2

3}

Affiliations

¹ Division of Hematology and Oncology, Perelman School of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia.
² Department of Oncology, Dell Medical School, University of Texas at Austin.
³ Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin.

Comment

Samuel U Takvorian et al. JAMA Netw Open. 2022.

. 2022 Mar 1;5(3):e224437.

doi: 10.1001/jamanetworkopen.2022.4437.

Samuel U Takvorian¹, Tara L Kaufmann^{2

3}

¹ Division of Hematology and Oncology, Perelman School of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia.
² Department of Oncology, Dell Medical School, University of Texas at Austin.
³ Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin.

No abstract available

Comment on

Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy: A Randomized Clinical Trial.
Zhang L, Zhang X, Shen L, Zhu D, Ma S, Cong L. Zhang L, et al. JAMA Netw Open. 2022 Mar 1;5(3):e224427. doi: 10.1001/jamanetworkopen.2022.4427. JAMA Netw Open. 2022. PMID: 35357459 Free PMC article. Clinical Trial.

1. Zhang L, Zhang X, Shen L, Zhu D, Ma S, Cong L. Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e224427. doi:10.1001/jamanetworkopen.2022.4427 - DOI - PMC - PubMed
1. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565. doi:10.1200/JCO.2015.63.0830 - DOI - PMC - PubMed
1. Denis F, Basch E,Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321(3):306–307 doi:10.1001/jama.2018.18085 - DOI - PMC - PubMed
1. Tolstrup LK, Bastholt L, Dieperink KB, Möller S, Zwisler AD, Pappot H. The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. J Patient Rep Outcomes. 2020;4(1):88. doi:10.1186/s41687-020-00255-0 - DOI - PMC - PubMed
1. Electronic patient reporting of symptoms during cancer treatment (PRO-TECT). ClinicalTrials.gov identifier: NCT03249090. Updated December 8, 2021. Accessed February 2, 2022. https://clinicaltrials.gov/ct2/show/NCT03249090